Gene clues reveal why some rare leukemia patients resist tagraxofusp therapy
medicalxpress - Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and …
AI Summary: Researchers have identified decreased TXNRD1 and related molecular changes that appear linked to resistance against tagraxofusp in BPDCN patients. This insight exposes a plausible resistance mechanism and opens opportunities to test predictive biomarkers or combination strategies to overcome failure, which is welcome news for clinicians facing a stubborn, high‑risk disease.
Two tests GPs can soon offer to help spot endometriosis
bbc - Experts hope they will be a game-changer and cut the nine-year or longer diagnosis waits patients can currently face.
AI Summary: Emerging research on hormonal signatures and blood biomarkers has led to development of tests GPs may soon use to spot endometriosis earlier. Patient accounts underline the life‑changing potential of timely diagnosis. The work promises less guesswork, fewer invasive procedures, and fewer years lost to unexplained pain—so yes, medicine might actually make life convenient for once.
A Legionnaires' Disease Outbreak Has Sickened 28 People in New York City — Here's What to Know
discovermagazine - Learn more about Legionnaires' disease and what the source of the current outbreak in New York City may be.
AI Summary: An outbreak of Legionnaires’ disease has sickened multiple residents and visitors on Manhattan’s Upper East Side, triggering public-health investigations, building inspections and water-system testing. Officials are working to identify the source and contain the spread while urging clinicians to consider Legionnaires’ in patients with pneumonia-like symptoms.
American Cancer Society Reports Latest Global Cancer Statistics; Cancer Cases Approach 21 Million Worldwide, With Burden Projected to Surge 67% by 2050
cancer - New data reveal stark geographic inequities and call for urgent global action on prevention, early detection, and equitable treatment access
AI Summary: The American Cancer Society published updated global cancer statistics showing cases near 21 million and projecting a steep rise by midcentury, highlighting shifting incidence patterns and growing health system strain. The report calls for intensified prevention, screening and investment in equitable cancer control to blunt the projected surge.
- GLOBOCAN and ACS: New global cancer estimates and projections (6)
- Regional responses: conferences, national programs, and research (4)
- Survival gaps: breast, GI, GU cancers and immunotherapy access (5)
- WHO 2026 Global Cancer Report: Urgent calls for action (5)
- All Other Stories
GLOBOCAN and ACS: New global cancer estimates and projections
Regional responses: conferences, national programs, and research
Survival gaps: breast, GI, GU cancers and immunotherapy access
WHO 2026 Global Cancer Report: Urgent calls for action
All Other Stories
Parham Habibzadeh: ctDNA MRD After CRLM Resection Identifies Who Benefits From ACT!
oncodaily - Parham Habibzadeh, Internal Medicine Resident at UPMC, shared a post on X: “JAMA Oncology: ctDNA MRD after CRLM resection identifies who benefits from ACT! Upfront surgery: MRD+ patients improved with […]
AI Summary: A growing body of evidence shows circulating tumor DNA (ctDNA) measured after colorectal liver metastasis resection can identify which patients truly benefit from adjuvant chemotherapy and who likely do not. This blood test promises more personalized postoperative care, reducing unnecessary toxicity and costs by targeting chemo to molecular minimal residual disease rather than gut instinct.
Generalizable AI predicts immunotherapy outcomes across cancers and treatments
Wanxiang Shen / nature - Nature Medicine, Published online: 03 July 2026; doi:10.1038/s41591-026-04502-7COMPASS is a pan-cancer foundation model that predicts immunotherapy response, across cancer types and treatments, from bulk tumor transcriptomes.
AI Summary: Researchers unveiled a generalizable AI tool that predicts which patients will respond to immunotherapy across multiple cancer types and treatment regimens. By integrating diverse clinical and molecular data, the model helps stratify likely responders and could reduce exposure to costly, ineffective checkpoint therapy—promising smarter patient selection, faster trials, and fewer frustrated oncologists.
- COMPASS paper: pan-cancer AI predicts immunotherapy response (3)
- Researchers and clinicians react on social media (3)
- All Other Stories
COMPASS paper: pan-cancer AI predicts immunotherapy response
Researchers and clinicians react on social media
All Other Stories
AI system detects sudden cardiac death risk, identifying thousands more patients annually
medicalxpress - Each year in the U.S., more than 300,000 people die from sudden cardiac arrest, a condition in which the heart's electrical system malfunctions without warning. The medical emergency can kill both high-risk older adults and young athletes with no history …
AI Summary: New AI tools claim to identify far more patients at risk of sudden cardiac death than traditional metrics, detecting subtle patterns invisible to clinicians. Early studies suggest strong sensitivity gains, but experts caution that screening scale‑up, false positives and prospective validation will determine whether the tech saves lives or simply creates more testing.
Generative AI-enabled clinical decision support system in primary care: a pragmatic, cluster-randomized trial
Ambrose Agweyu / nature - Nature Medicine, Published online: 26 June 2026; doi:10.1038/s41591-026-04503-6A pragmatic cluster-randomized trial found that ChatGPT-4o-assisted decision support in Kenyan primary care facilities did not significantly reduce 14-day treatment failure ove…
AI Summary: A pragmatic, cluster‑randomized trial showed that a generative AI clinical decision support tool improved clinician decision‑making in real‑world primary care settings. The results suggest practical benefits beyond pilot hype, though implementation, safety and privacy challenges remain on the checklist before widescale roll‑out.
Jeremy Clarkson’s Prostate Cancer Story: Early Detection, Treatment, and Remission
oncodaily - Jeremy Clarkson has revealed that he was diagnosed with an aggressive form of prostate cancer that was caught early. The broadcaster shared the diagnosis in the final episodes of Clarkson’s […]
AI Summary: Jeremy Clarkson publicly revealed an aggressive prostate cancer diagnosis, underwent early detection and treatment, and is now in remission. The case highlights the value of prompt screening and modern therapies — and proves even TV personalities can be very boringly human when faced with routine medicine.
Ebola outbreak is 3x larger at 4 weeks than any before: 6 updates
Mariah Taylor / beckershospitalreview - The current Bundibugyo Ebola outbreak is three times larger than any previous Ebola outbreak four weeks after being declared a public health emergency, Africa CDC epidemiologist Wessam Mankoula, MD, said in a briefing. The largest Ebola outbreak in histor…
AI Summary: The Ebola outbreak has escalated rapidly, outpacing previous episodes with case counts multiplying within weeks and official tallies surpassing 1,000 in affected regions. Clinicians note that current presentations can begin like a mild flu, raising detection challenges even as mortality remains significant. Public-health teams warn vigilance and rapid response remain critical.
- Milder symptoms complicate detection; treatment trials begin (5)
- Outbreak surges and regional spread (6)
- U.S. and global emergency response ramps up (4)
- All Other Stories
Milder symptoms complicate detection; treatment trials begin
Outbreak surges and regional spread
U.S. and global emergency response ramps up
All Other Stories
Early-onset cancers are on the rise: Knowing family history is crucial
medicalxpress - In the U.S., more than a dozen kinds of cancer are on the rise in adults under 50. Among these early-onset cancers, colorectal and breast cancers have increased the most, and colorectal cancer is now the deadliest cancer for Americans ages 18 to 49.
AI Summary: New analyses show early‑onset cancers are increasing and reinforce that detailed family history remains a key tool for risk assessment and targeted screening. Experts urged clinicians and health systems to prioritize family‑history collection and cascade testing to catch at‑risk individuals sooner and reduce preventable morbidity.
- Breast cancer risk: AI tools, polygenic scores, prevention (5)
- Colorectal cancer: rising cases and screening gaps worldwide (6)
- Faster biological aging linked to early-onset cancer rise (5)
- Inherited cancer risk and genomics driving early diagnoses (6)
- All Other Stories
Breast cancer risk: AI tools, polygenic scores, prevention
Colorectal cancer: rising cases and screening gaps worldwide
Faster biological aging linked to early-onset cancer rise
Inherited cancer risk and genomics driving early diagnoses
All Other Stories
Novel electronic health record-based marker can identify at-risk transplant patients and reduce organ rejection
medicalxpress - A new multicenter study led by researchers at the Icahn School of Medicine at Mount Sinai suggests that a novel electronic health record-based marker can help clinicians identify transplant patients at high risk for organ rejection because they are not ta…
AI Summary: Teams developed and validated an electronic‑health‑record derived marker that flags transplant recipients at elevated risk of organ rejection. The tool integrates routinely collected clinical data to trigger earlier review and intervention, promising to reduce rejection events if deployed thoughtfully within clinical workflows rather than buried in another alert pile.
IRhythm discloses data stolen from third-party applications in cyberattack
Ricky Zipp / healthcaredive - The cardiac monitoring company said that a threat actor has demanded payment in exchange for not publicly releasing the stolen data.
AI Summary: IRhythm announced a cybersecurity incident involving stolen data from third‑party applications and is investigating the breach. Limited patient information may have been exposed, prompting notifications and security reviews. The episode starkly illustrates how digital‑health vendors remain attractive targets and how compromises of ancillary systems can ripple into real patient risk.
Rishabh Jain: What ALTAIR Teaches Us About ctDNA-Positive CRC
oncodaily - Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X: “ctDNA-positive CRC after curative surgery sounds like the perfect place to intervene. But ALTAIR says: not so fast. Phase 3, double-blind […]
AI Summary: Coverage examines ALTAIR, a randomized phase‑3 trial testing post‑adjuvant chemotherapy for patients with resected colorectal cancer who are ctDNA‑positive. Experts dissect trial design, endpoints and implications for ctDNA‑guided treatment decisions, debating whether circulating tumor DNA should steer adjuvant therapy or remain an elegant biomarker with stubborn practical hurdles.
Ultrasensitive blood test predicts head and neck cancer relapse months earlier
medicalxpress - A new study by investigators from Mass General Brigham Cancer Institute has found that an ultrasensitive blood test called HPV-DeepSeek could help identify which people with HPV-associated head and neck cancer still had cancer cells in their bodies after …
AI Summary: Researchers validated an ultrasensitive HPV whole‑genome sequencing blood assay that detects minimal residual disease after surgery for HPV‑positive head and neck cancer, flagging relapse months before clinical signs. Early detection could enable earlier salvage therapy and closer surveillance, potentially changing follow‑up care and improving outcomes for this patient group.
Florian Lordick Elected ESMO President 2029–2030
oncodaily - Professor Florian Lordick has been elected President of the European Society for Medical Oncology for the 2029–2030 term, marking a new leadership chapter for one of the world’s leading oncology […]
AI Summary: Florian Lordick will serve as ESMO president for 2029–2030, pledging to prioritise precision oncology, workforce development and stronger European collaboration. Colleagues praise his vision for translating research into practice and amplifying policy advocacy; expectations include initiatives to close care gaps and bolster international partnerships — because someone has to herd this many oncologists.
Genital herpes rising in England, despite overall drop in STIs
bbc - STIs are particularly common among young people, with health experts saying testing for them is vital.
AI Summary: Public-health surveillance shows genital herpes cases climbing in England even as many other sexually transmitted infections fall. Experts warn the uptick signals gaps in prevention, testing and sexual-health services, underscoring the need for better awareness and targeted care rather than assuming the problem will fix itself. Yes, herpes is back on the agenda.
Argentina expands hantavirus probe, sending teams to trap and test rats in Mendoza
medicalxpress - Argentina on Friday said it was expanding its investigation into the origins of the hantavirus outbreak that struck an Atlantic cruise ship last month, sending scientists to trap and test rats in the western province of Mendoza while lab results are pendi…
AI Summary: Argentinian health authorities have expanded an investigation in Mendoza after hantavirus concerns, dispatching teams to trap and test wild rodents for infection. The stepped-up fieldwork aims to map viral reservoirs and potential human exposure, while officials warn residents to take basic precautions — because nothing says 'welcome to town' like a rat-capture detail.
WellSpan Health, Philips launch 7-year AI, imaging partnership
Naomi Diaz / beckershospitalreview - York, Pa.-based WellSpan Health and Royal Philips have entered a seven-year strategic alliance covering advanced imaging technology, AI-enabled care and a joint research and co-development agreement across WellSpan’s 12 hospitals, diagnostic imaging cente…
AI Summary: WellSpan Health and Philips announced a seven-year collaboration to co-develop and deploy AI-enabled imaging solutions across the health system. The agreement aims to accelerate diagnostic imaging innovation, integrate AI into clinical workflows and support research — effectively a bet that smarter machines can shave time off scans and maybe improve patient outcomes.
LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC
oncodaily - LIBRETTO-432 Trial was presented during ASCO 2026 by Jonathan W. Goldman, MD, as a global, multicenter, phase 3, double-blind, randomized, placebo-controlled study evaluating adjuvant selpercatinib in patients with early-stage RET […]
AI Summary: At ASCO26 plenary, LIBRETTO‑432 data show adjuvant selpercatinib markedly prolongs event‑free survival and slashes recurrence risk for patients with stage II–IIIA RET fusion–positive non‑small cell lung cancer after curative treatment. The findings support a new standard for this rare genetic subgroup and press the case for routine genomic testing.